X
11Nov

COVID-19 Report for Life Sciences and Health Care Companies (UPDATED)

Hogan Lovells | | Return|
In Tuesday's Report: the expanding role of real-world evidence in FDA medical device submissions; President-elect Joe Biden lays out COVID-19 plan; Pfizer announces vaccine efficacy; and an analysis of material adverse change (MAC) clauses in Japan....
By: Hogan Lovells
Source Url: https://www.jdsupra.com/legalnews/covid-19-report-for-life-sciences-and-24214/

Related

Financial Daily Dose 8.28.2019 | Top Story: British PM to Suspend Parliament in Bid to Push Through Brexit

Man-of-the-people PM Boris Johnson is set to as the Queen to suspend parliament for 5 weeks in an at...

Read More >

The Effect Of The COVID-19 Coronavirus On Construction

The COVID-19 coronavirus is impacting every aspect of the economy, and construction will not be exem...

Read More >

Sweeping New Illinois Law Mandates Sex Harassment Training, Restricts Use of Arbitration and Non-Disclosure Agreements, and Much More

On August 9, 2019, Illinois Governor J.B. Pritzker signed into law a sweeping piece of legislation, ...

Read More >

Changing Roles: the CMA during the Transition Period and beyond

As the UK departs the European Union, the CMA – the UK competition regulator – is facing a transfo...

Read More >

Not All Damages Are Created Equal – the Proper Application of the Economic Loss Doctrine

In William Lansing v. Doe, 2019 Ore. App. LEXIS 1564, the Court of Appeals of Oregon considered whet...

Read More >